Solid Biosciences SLDB
NASDAQ SLDB
$7.60 +0.43 (+6.00%)
At close: Nov 11, 2026 · 4:00 PM EST

Solid Biosciences (SLDB) Net Income Attributable to Noncontrolling Interests (2017)

Updated

Solid Biosciences (SLDB) recorded Income from Non-Controlling Interests of -$1.06 million in FY2017, compared with -$2.23 million in FY2016.

Analysis

Solid Biosciences (SLDB) Net Income Attributable to Noncontrolling Interests (2017) Analysis & Trends

  • Per Business Quant data, SLDB's Income from Non-Controlling Interests was -$2.23 million in FY2016.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) NCI Net Income (Qtr)
1 Eli Lilly 1,348.13 Bn 1,321.74 Bn 20.46 Bn -
2 Johnson & Johnson 675.90 Bn 595.76 Bn 17.30 Bn -
3 AbbVie 519.45 Bn 487.50 Bn 13.12 Bn 2.00 Mn
4 Merck 364.95 Bn 327.95 Bn 13.19 Bn 2.00 Mn
5 Novartis Ag 311.58 Bn 285.16 Bn - -
6 Astrazeneca 289.34 Bn 262.94 Bn 13.26 Bn -1.00 Mn
7 Amgen 251.64 Bn 203.30 Bn 7.58 Bn -
8 Gilead Sciences 212.05 Bn 187.07 Bn 6.73 Bn -
9 Pfizer 167.35 Bn 115.00 Bn 12.56 Bn 10.00 Mn
10 Solid Biosciences 1.08 Bn -212.24 Mn - -
Historic Data

Historic Data

Download Data
DateValue
Mar 31, 2017 -1.06 Mn
API Access

Solid Biosciences Net Income Attributable to Noncontrolling Interests API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=income-from-non-controlling-interests&ticker=SLDB&period=max&api_key=YOUR_API_KEY